Sutro Biopharma, Inc.
STRO
$0.8504
-$0.0522-5.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -333.20% | 1.01% | -24.64% | -16.31% | 189.80% |
| Total Depreciation and Amortization | 7.91% | 3.45% | 3.41% | 9.04% | 13.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 410.05% | -201.04% | 421.12% | -29.76% | 127.57% |
| Change in Net Operating Assets | 27.09% | -290.27% | 514.23% | 31.93% | -210.30% |
| Cash from Operations | -609.79% | -92.57% | 130.31% | -6.15% | 158.97% |
| Capital Expenditure | 25.88% | -152.44% | 52.87% | 52.65% | 57.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 501.21% | 230.28% | -217.50% | -5.62% | 36.05% |
| Cash from Investing | 472.08% | 229.18% | -221.49% | -4.96% | 37.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | -30.66% | 0.00% |
| Issuance of Common Stock | -- | 14.36% | 9,110.59% | -91.67% | -100.00% |
| Repurchase of Common Stock | -- | -124.24% | -516.67% | 17.07% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99.23% | 117.72% | -29.91% | -139.15% | -125.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 225.15% | 154.67% | -85.19% | -126.71% | 74.63% |